Novo Nordisk says Wegovy reduced risk of adverse cardiovascular events by 20% in adults with obesity in trial

Obesity drug shows positive results in tackling some of the other health issues caused by being overweight.

Related Keywords

Denmark ,Danish ,Novo Nordisk Us Listed ,Martin Holst Lange ,Novo Nordisk ,Article Normal ,Biotechnology ,Pharmaceuticals ,Machinery ,Agricultural Machinery ,Wholesalers ,Retail Wholesale ,Health Care ,Industrial Goods ,Regulation Government Policy ,Financial Performance ,Earnings ,Corporate Industrial News ,Political General News ,Society Community ,Diabetes ,Food Drink ,Health ,Living Lifestyle ,Medical Conditions ,Nutrition ,Obesity ,Social Issues ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Novo Nordiskas Series B ,Dk Novo B ,Novo Nordiskas Adr ,Nvo ,Pfizer Inc ,Pfe ,Regulation ,Government Policy ,Corporate ,Industrial News ,Political ,General News ,Society ,Community ,Food ,Drink ,Living ,Lifestyle ,Retail ,Wholesale ,